What is largely missing is the tier that decides clinical questions: randomized, controlled, blinded human trials with objective endpoints
Topical Copper Peptides Affects surface layers of skin only Limited penetration through skin barrier Localized effect only where applied Good for maintenance, not transformation No systemic anti-aging benefit Available over-the-counter Injectable GHK-Cu Full systemic delivery to all tissues Reaches dermis, follicles, and healing sites Whole-body anti-aging effect More potent collagen stimulation Gene expression modulation (4,000+ genes) Requires medical prescription They are not mutually exclusive
Across preclinical studies, Epitalon has shown: Telomerase activation and telomere extension: Via TRAP assays and fibroblast lifespan extension beyond the Hayflick limit Epigenetic remodeling: Reversal of chromatin aging, histone modulation, and gene promoter binding Redox homeostasis: Increased antioxidant enzymes (SOD, NQO1, catalase) and reduced ROS, lipid peroxidation, and DNA damage Circadian restoration: Upregulation of AANAT/pCREB, normalized melatonin and cortisol rhythms, and clock gene modulation in humans Cancer risk reduction: Reduced tumor multiplicity and delayed onset in HER-2/neu and colon cancer models
That is marketing
Studies examine its influence on signaling pathways involved in cell renewal and adaptive responses
